FDA Looks into Pradaxa Bleeding Risk; What Does it Mean for PGx-Guided Warfarin Dosing?
December 14, 2011
FDA Looks into Pradaxa Bleeding Risk; What Does it Mean for PGx-Guided Warfarin Dosing?
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- When Might Warfarin PGx Be Better Than Pradaxa? Stakeholders Weigh In
October 27, 2010 / Pharmacogenomics Reporter - FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios
July 13, 2011 / Pharmacogenomics Reporter - FDA Updates Warfarin Labeling with PGx-Guided Dosing Ranges
February 3, 2010 / Pharmacogenomics Reporter - Following Merger, Express Scripts May Cut Back Medco's Personalized Medicine Programs
May 9, 2012 / Pharmacogenomics Reporter - Top 10 PGx Reporter Stories in 2010: Scientific, Business, and Legislative Issues Loom Large
January 5, 2011 / Pharmacogenomics Reporter